Investment case
Biogen Inc.
BIIB · 40 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 40 macro, policy, and market developments to Biogen Inc. since 2026-08-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for BIIB yet, so no modelled value is shown. The BIIB valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run BIIB on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
Increased investor interest in companies with strong neuroscience and rare disease pipelines, potential for future pipeline expansion or partnerships in cardiovascular diseases.
· Moves probability of success pipeline, addressable market size, r&d efficiency
- Main threat
FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
Increased competition in the Spinal Muscular Atrophy (SMA) market, potential erosion of market share for Spinraza.
· Moves peak sales estimates for spinraza, market share assumptions for spinraza, pricing power for existing sma therapies
- Open question
Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
Increased competition in neurodegenerative disease space, potential for new therapeutic approaches to influence R&D strategies.
· Moves pipeline valuation, future r&d spend
What changed, by assumption
- 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
- 2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
- 2026-09-12FDA Approves Isembyld for Spinal Muscular Atrophy
- 2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials
- 2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
- 2026-09-01Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Oncolytics Biotech Inc Announces Publication of Pelareorep Liver Cancer Data | watch | 3-12m | 0.10 |
| 2026-09-29 | Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Priority Review Voucher | watch | 3-12m | 0.20 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share | watch | 3-12m | 0.20 |
| 2026-09-24 | Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease | watch | 3-12m | 0.40 |
| 2026-09-24 | Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies | watch | 3-12m | 0.30 |
| 2026-09-24 | Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs | watch | 3-12m | 0.30 |
| 2026-09-23 | Roche to Acquire Ionis Pharmaceuticals, Inc. | watch | 3-12m | 0.30 |
| 2026-09-21 | Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen | Bearish | 3-12m | 0.20 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | watch | 3-12m | 0.20 |
| 2026-09-21 | Ionis slides over 40% year-to-date following late-stage clinical setbacks | Bearish | 1-3m | 0.30 |
| 2026-09-21 | Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks | Bearish | 3-12m | 0.20 |
| 2026-09-21 | Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks | Bearish | 3-12m | 0.30 |